Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608216 · ClinicalTrials.gov registry record · Phase 1
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
A Phase 1 study of Metastatic Breast Cancer and Breast Neoplasm, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02608216 is a Phase 1 study of Metastatic Breast Cancer and Breast Neoplasm that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 20 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02608216, a Phase 1 study of Metastatic Breast Cancer and Breast Neoplasm, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT).
Conditions Studied
Interventions
- DRUG ribociclib
- DRUG paclitaxel
- DEVICE PET/CT
- DRUG [18F]FLT
Study Locations (1)
Pennsylvania
- University of Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-11 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608216
The ClinicalTrials.gov registry entry for NCT02608216 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (90% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which ribociclib is the first listed.
NCT02608216 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02608216 about?
NCT02608216 is a clinical study titled "[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer". In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluorothymidine (FLT).
What is the current status of trial NCT02608216?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-11. Estimated completion is 2026-11.
What conditions does trial NCT02608216 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Breast Neoplasm, Rb+ Breast Cancer.
What interventions are being tested in trial NCT02608216?
The interventions under investigation include: ribociclib (DRUG), paclitaxel (DRUG), PET/CT (DEVICE), [18F]FLT (DRUG).
Who is sponsoring clinical trial NCT02608216?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02608216 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.